Confronto
Dulaglutide vs. Semaglutid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
923950-08-7
910463-68-2
Peso molecolare
59670 g/mol
4113.6 g/mol
Emivita
110 h
165 h
Sequenza
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-Fcmodifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMeccanismo d'azione
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
5
4
di cui sull'uomo
5
3
Effetti registrati
3
3
Contraddizioni aperte
1
1
Eventi avversi documentati
2
5
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Dulaglutide and Semaglutid?
- Dulaglutide is classified as "Metabolico", while Semaglutid is classified as "Metabolico". Dulaglutide: GLP-1 receptor agonist designed as a fusion protein of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc fragment. FDA-approved 2014 (Trulicity) for type 2 diabetes; EMA approval 2014. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Dulaglutide or Semaglutid?
- The highest available evidence level is "RCT sull'uomo" for Dulaglutide and "RCT sull'uomo" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Dulaglutide and Semaglutid in Germany and the United States?
- Germania: Dulaglutide — Su prescrizione, Semaglutid — Su prescrizione. Stati Uniti: Dulaglutide — Su prescrizione, Semaglutid — Su prescrizione. These are factual summaries with source and review date on the individual pages.